These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 28847246)

  • 21. Application of the 2015 proposed NIOSH vapor containment performance protocol for closed system transfer devices used during pharmacy compounding and administration of hazardous drugs.
    Forshay CM; Streeter SO; Salch SA; Eckel SF
    J Oncol Pharm Pract; 2019 Jul; 25(5):1160-1166. PubMed ID: 30041583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The PhaSeal® system: impact of its use on workplace contamination and duration of chemotherapy preparation.
    Favier B; Labrosse H; Gilles-Afchain L; Cropet C; Perol D; Chaumard N; Latour JF; Hild P
    J Oncol Pharm Pract; 2012 Mar; 18(1):37-45. PubMed ID: 21422148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacist-oriented drug distribution systems.
    Freedman GI
    Am J Hosp Pharm; 1985 Feb; 42(2):383-5. PubMed ID: 3976689
    [No Abstract]   [Full Text] [Related]  

  • 24. Economic assessment of aseptic compounding rooms in hospital pharmacies in five European countries.
    Dekyndt B; Décaudin B; Lannoy D; Odou P
    J Oncol Pharm Pract; 2015 Apr; 21(2):102-10. PubMed ID: 24519187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Occupational exposure to anti-cancer drugs: A review of effects of new technology.
    Vyas N; Yiannakis D; Turner A; Sewell GJ
    J Oncol Pharm Pract; 2014 Aug; 20(4):278-87. PubMed ID: 23975555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative parallel assessment of a transfer device in reducing 5-fluorouracil environmental contamination inside positive air pressure isolators.
    Forges F; Simoens X; Chauvin F
    J Oncol Pharm Pract; 2011 Mar; 17(1):61-7. PubMed ID: 20699332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of a closed-system cytotoxic transfer device in a pharmaceutical isolator.
    Vyas N; Turner A; Clark JM; Sewell GJ
    J Oncol Pharm Pract; 2016 Feb; 22(1):10-9. PubMed ID: 25073678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative study of contamination in three closed systems for the preparation of hazardous drugs through simulations with fluorescein.
    González-Haba-Peña E; Manrique-Rodríguez S; Herranz-Alonso AM; Iglesias-Peinado I; Sanjurjo-Sáez M
    Farm Hosp; 2018 Nov; 42(6):234-238. PubMed ID: 30381043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implementation and evaluation of a sterile compounding robot in a satellite oncology pharmacy.
    Bhakta SB; Colavecchia AC; Coffey W; Curlee DR; Garey KW
    Am J Health Syst Pharm; 2018 Jun; 75(11 Supplement 2):S51-S57. PubMed ID: 29802179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost of implementing Veterans Administration directives for handling antineoplastic agents.
    Murphy CP; Goldspiel BR; Koeller J
    Am J Hosp Pharm; 1987 Apr; 44(4):788-91. PubMed ID: 3578312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surface contamination of cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden.
    Hedmer M; Georgiadi A; Bremberg ER; Jönsson BA; Eksborg S
    Ann Occup Hyg; 2005 Oct; 49(7):629-37. PubMed ID: 16126760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the "make or buy" decision for oral solid unit-dose medications.
    Yeoman AE
    Contemp Pharm Pract; 1979; 2(4):182-5. PubMed ID: 10309070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adherence to Precautionary Guidelines for Compounding Antineoplastic Drugs: A Survey of Nurses and Pharmacy Practitioners.
    Boiano JM; Steege AL; Sweeney MH
    J Occup Environ Hyg; 2015; 12(9):588-602. PubMed ID: 25897702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pressure Compatibility Test of Closed System Drug Transfer Devices for 71 Anticancer Drugs].
    Ishimaru H; Tsuda Y; Kage H; Kawano T; Takayama S; Morimoto Y; Goto K; Watanabe K
    Yakugaku Zasshi; 2021; 141(1):143-150. PubMed ID: 33390441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of drug contamination levels in an admixture preparation area.
    Christenson I; Jansson B
    J Clin Hosp Pharm; 1983 Sep; 8(3):241-5. PubMed ID: 6313768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reusing cytostatics in a centralised pharmacy preparation unit.
    Ramos Linares S; Merino Alonso J; Román González N; Tévar Alfonso E; Díaz Ruíz P; Gorchs Molist M
    Farm Hosp; 2011; 35(2):70-4. PubMed ID: 20869287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of economic data on closed system transfer drug for preparation and administration of hazardous drugs.
    Soubieux A; Tanguay C; Lachaine J; Bussières JF
    Eur J Hosp Pharm; 2020 Nov; 27(6):361-366. PubMed ID: 33097620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economics of providing antineoplastic drugs in a manufacturer-mixed bulk package.
    Kleinberg ML; Duafala ME
    Am J Hosp Pharm; 1988 Jan; 45(1):109-15. PubMed ID: 3348222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of a closed system drug-transfer device eliminates surface contamination with antineoplastic agents.
    Clark BA; Sessink PJ
    J Oncol Pharm Pract; 2013 Jun; 19(2):99-104. PubMed ID: 23292973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of real-time data obtained from gravimetric preparation of antineoplastic agents shows medication errors with possible critical therapeutic impact: Results of a large-scale, multicentre, multinational, retrospective study.
    Terkola R; Czejka M; Bérubé J
    J Clin Pharm Ther; 2017 Aug; 42(4):446-453. PubMed ID: 28429389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.